SG149676A1 - Use of hypoglycemic agent for treating impaired glucose metabolism - Google Patents
Use of hypoglycemic agent for treating impaired glucose metabolismInfo
- Publication number
- SG149676A1 SG149676A1 SG200403826-1A SG2004038261A SG149676A1 SG 149676 A1 SG149676 A1 SG 149676A1 SG 2004038261 A SG2004038261 A SG 2004038261A SG 149676 A1 SG149676 A1 SG 149676A1
- Authority
- SG
- Singapore
- Prior art keywords
- prevention
- impaired glucose
- reduction
- hypoglycemic agent
- glucose metabolism
- Prior art date
Links
- 239000003472 antidiabetic agent Substances 0.000 title abstract 2
- 230000004153 glucose metabolism Effects 0.000 title abstract 2
- 229940126904 hypoglycaemic agent Drugs 0.000 title abstract 2
- 230000001771 impaired effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 4
- 208000002705 Glucose Intolerance Diseases 0.000 abstract 2
- 206010056997 Impaired fasting glucose Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 230000034994 death Effects 0.000 abstract 1
- 231100000517 death Toxicity 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 1
- 229960001254 vildagliptin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99125761 | 1999-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG149676A1 true SG149676A1 (en) | 2009-02-27 |
Family
ID=8239709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200403826-1A SG149676A1 (en) | 1999-12-23 | 2000-12-04 | Use of hypoglycemic agent for treating impaired glucose metabolism |
Country Status (18)
Country | Link |
---|---|
US (6) | US6949555B2 (ko) |
EP (1) | EP1239854A1 (ko) |
JP (3) | JP2003518496A (ko) |
KR (3) | KR20100028131A (ko) |
CN (2) | CN1413107A (ko) |
AU (2) | AU777776B2 (ko) |
BR (1) | BR0016631A (ko) |
CA (1) | CA2393083C (ko) |
HU (1) | HUP0600522A2 (ko) |
IL (3) | IL150204A0 (ko) |
NO (1) | NO20022979L (ko) |
NZ (2) | NZ531929A (ko) |
PL (1) | PL355761A1 (ko) |
RU (1) | RU2264811C2 (ko) |
SG (1) | SG149676A1 (ko) |
SK (1) | SK8902002A3 (ko) |
WO (1) | WO2001047514A1 (ko) |
ZA (1) | ZA200204959B (ko) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6878749B2 (en) * | 1999-09-17 | 2005-04-12 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
BR0016631A (pt) * | 1999-12-23 | 2003-01-07 | Novartis Ag | Uso de agentes hipoglicêmico para tratar metabolismo de glicose depreciada |
SK14922002A3 (sk) * | 2000-03-17 | 2003-04-01 | Ajinomoto Co., Inc. | Farmaceutický prostriedok na prevenciu, zlepšenie a/alebo liečenie diabetickej komplikácie a použitie postprandiálnej látky na zníženie hladiny krvného cukru |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
PT1642885E (pt) | 2000-08-29 | 2009-12-17 | Biocon Ltd | Utilização de uma composição farmacêutica contendo um derviado de ácido para-aminofenilacético para o tratamento de estados inflamatórios do tracto gastrointestinal |
US8048924B2 (en) | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
CA2478599A1 (en) * | 2002-03-11 | 2003-09-18 | Novartis Ag | Salts of nateglinide |
US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
DK1529058T3 (da) * | 2002-03-20 | 2013-12-02 | Us Of America As Represented By The Dept Of Veterans Affairs | Ikke-selektiv kationkanal i nerveceller og sur1-antagonister til behandling af hjernehævelse |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7790681B2 (en) * | 2002-12-17 | 2010-09-07 | Amylin Pharmaceuticals, Inc. | Treatment of cardiac arrhythmias with GLP-1 receptor ligands |
US20040209803A1 (en) * | 2002-12-19 | 2004-10-21 | Alain Baron | Compositions for the treatment and prevention of nephropathy |
WO2005013964A1 (ja) | 2003-08-08 | 2005-02-17 | Ajinomoto Co., Inc. | ナテグリニド含有製剤 |
CN1905876B (zh) * | 2003-11-17 | 2010-06-09 | 诺瓦提斯公司 | 二肽基肽酶iv抑制剂的用途 |
US20050163837A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone formulations |
US20050163842A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Rosiglitazone and metformin formulations |
WO2005094812A1 (ja) * | 2004-04-01 | 2005-10-13 | Ajinomoto Co., Inc. | ナテグリニド含有製剤 |
EP1773767B1 (en) | 2004-07-07 | 2016-03-09 | Biocon Limited | Synthesis of azo bonded immunoregulatory compounds |
AU2005290238A1 (en) * | 2004-09-18 | 2006-04-06 | Department Of Veterans Affairs | Therapeutic agents trageting the NCCa-ATP channel and methods of use thereof |
ATE487484T1 (de) * | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
JP4974057B2 (ja) * | 2005-01-31 | 2012-07-11 | 味の素株式会社 | 血糖降下剤を含有する、耐糖能異常、境界型糖尿病、インスリン抵抗性及び高インスリン血症の改善ないし治療用医薬組成物 |
JP4822204B2 (ja) * | 2005-07-06 | 2011-11-24 | 国立大学法人神戸大学 | 血糖降下薬作用予測システム |
JP4094660B1 (ja) * | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
WO2007101179A2 (en) * | 2006-02-28 | 2007-09-07 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Enterostatin as therapeutic agent for hypoglycemia |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
CA2810522A1 (en) | 2006-05-04 | 2007-11-15 | Boehringer Ingelheim International Gmbh | Polymorphs |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
EP2111224B1 (en) * | 2007-01-12 | 2016-07-13 | University of Maryland, Baltimore | Targeting ncca-atp channel for organ protection following ischemic episode |
EP2114160B1 (en) * | 2007-02-09 | 2016-11-16 | University of Maryland, Baltimore | Antagonists of a non-selective cation channel in neural cells |
CA3065983C (en) | 2007-06-22 | 2022-07-26 | The United States Of America As Represented By The Department Of Veterans Affairs | Inhibitors of ncca-atp channels for therapy |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
CN101548972B (zh) * | 2008-04-03 | 2012-10-17 | 万特制药(海南)有限公司 | 一种含有瑞格列奈的固体药物组合物 |
US8563730B2 (en) | 2008-05-16 | 2013-10-22 | Takeda San Diego, Inc. | Pyrazole and fused pyrazole glucokinase activators |
KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
KR102668834B1 (ko) | 2009-11-27 | 2024-05-24 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
CN102946875A (zh) | 2010-05-05 | 2013-02-27 | 贝林格尔.英格海姆国际有限公司 | 组合疗法 |
AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
CN104127423A (zh) * | 2014-07-30 | 2014-11-05 | 沈阳药科大学 | 格列喹酮衍生物及其制备方法和应用 |
CN104127424A (zh) * | 2014-07-30 | 2014-11-05 | 沈阳药科大学 | 格列本脲衍生物及其制备方法和应用 |
MX2018015089A (es) | 2016-06-10 | 2019-05-13 | Boehringer Ingelheim Int | Combinacion de linagliptina y metformina. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000034241A1 (en) * | 1998-12-10 | 2000-06-15 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
ZA985126B (en) * | 1997-06-13 | 1998-12-14 | Novo Nordisk As | Novel niddm regimen |
IL143004A0 (en) * | 1998-11-11 | 2002-04-21 | Smithkline Beecham Plc | Combinations comprising a beta-agonist and a further antidiabetic agent |
CZ20011629A3 (cs) * | 1998-11-12 | 2001-12-12 | Smithkline Beecham Plc | Farmaceutický prostředek pro upravené uvolňování senzitizéru inzulínu a jiných antidiabetických přípravků |
US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
US6878749B2 (en) * | 1999-09-17 | 2005-04-12 | Novartis Ag | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
BR0016631A (pt) * | 1999-12-23 | 2003-01-07 | Novartis Ag | Uso de agentes hipoglicêmico para tratar metabolismo de glicose depreciada |
-
2000
- 2000-12-04 BR BR0016631-6A patent/BR0016631A/pt not_active Application Discontinuation
- 2000-12-04 HU HU0600522A patent/HUP0600522A2/hu unknown
- 2000-12-04 SK SK890-2002A patent/SK8902002A3/sk not_active Application Discontinuation
- 2000-12-04 AU AU30059/01A patent/AU777776B2/en not_active Ceased
- 2000-12-04 RU RU2002119558/15A patent/RU2264811C2/ru not_active IP Right Cessation
- 2000-12-04 JP JP2001548109A patent/JP2003518496A/ja active Pending
- 2000-12-04 KR KR1020107003831A patent/KR20100028131A/ko not_active Application Discontinuation
- 2000-12-04 KR KR1020107026905A patent/KR20100130651A/ko not_active Application Discontinuation
- 2000-12-04 IL IL15020400A patent/IL150204A0/xx unknown
- 2000-12-04 PL PL00355761A patent/PL355761A1/xx not_active IP Right Cessation
- 2000-12-04 KR KR1020027008143A patent/KR20020063260A/ko not_active Application Discontinuation
- 2000-12-04 CN CN00817649A patent/CN1413107A/zh active Pending
- 2000-12-04 SG SG200403826-1A patent/SG149676A1/en unknown
- 2000-12-04 CN CNA2006101159985A patent/CN1911221A/zh active Pending
- 2000-12-04 EP EP00990641A patent/EP1239854A1/en not_active Ceased
- 2000-12-04 NZ NZ531929A patent/NZ531929A/en not_active IP Right Cessation
- 2000-12-04 NZ NZ519231A patent/NZ519231A/en not_active IP Right Cessation
- 2000-12-04 WO PCT/EP2000/012174 patent/WO2001047514A1/en active Application Filing
- 2000-12-04 CA CA2393083A patent/CA2393083C/en not_active Expired - Fee Related
- 2000-12-06 US US09/731,139 patent/US6949555B2/en not_active Expired - Fee Related
-
2002
- 2002-06-12 IL IL150204A patent/IL150204A/en not_active IP Right Cessation
- 2002-06-20 NO NO20022979A patent/NO20022979L/no not_active Application Discontinuation
- 2002-06-20 ZA ZA200204959A patent/ZA200204959B/en unknown
-
2004
- 2004-07-06 US US10/885,057 patent/US20040242647A1/en not_active Abandoned
- 2004-09-10 US US10/939,002 patent/US20050043362A1/en not_active Abandoned
-
2005
- 2005-01-21 AU AU2005200398A patent/AU2005200398B2/en not_active Ceased
-
2006
- 2006-01-25 US US11/339,188 patent/US20060122244A1/en not_active Abandoned
- 2006-09-14 JP JP2006249499A patent/JP2006328091A/ja active Pending
- 2006-10-17 US US11/581,891 patent/US20070032538A1/en not_active Abandoned
-
2008
- 2008-07-28 US US12/180,689 patent/US20080287501A1/en not_active Abandoned
-
2011
- 2011-05-09 JP JP2011104450A patent/JP2011153155A/ja active Pending
- 2011-05-19 IL IL213041A patent/IL213041A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000034241A1 (en) * | 1998-12-10 | 2000-06-15 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
Non-Patent Citations (2)
Title |
---|
IMPROVED MEAL-RELATED BETA-CELL FUNCTION AND INSULIN SENSITIVITY BY * |
THE DIPEPTIDYL PEPTIDASE-IV INHIBITOR VILAGLIPTIN IN METFORMIN-TREATED * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG149676A1 (en) | Use of hypoglycemic agent for treating impaired glucose metabolism | |
USD426308S (en) | Breast wrap | |
TW200607509A (en) | Use of optically pure (S,S) -reboxetine in the manufacture of a medicament for the treatment or prevention of chronic fatigue syndrome | |
WO2003053219A3 (en) | Methods for slowing senescence and treating and preventing diseases associated with senescence | |
IL142864A0 (en) | Compositions and methods for producing vascular occlusion | |
EP1935427A3 (en) | Uses of soluble CTLA4 mutant molecules | |
MXPA02007915A (es) | Mediador de lipido activado por aspirina. | |
WO2002102394A3 (en) | Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases, arthritis, skin cancer, diabetes, premenstrual syndrome and transdermal transport | |
PL331822A1 (en) | Application of a chelating agent clioquinole in production of a pharmaceutic agent designed for use in treatment of alzheimer disease | |
IL178952A0 (en) | Use of ether compounds and pharmaceutically acceptable salts thereof for the preparation of a medicament for treating or preventing a cardiovascular disease | |
MY127685A (en) | Levodopa/carbidopa/entacapone pharmaceutical preparation | |
ES2192880T3 (es) | Agente terapeutico para la represion de ruidos originados por ronquidos. | |
WO2001010426A3 (en) | Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer | |
WO2003055979A3 (en) | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS | |
GB2368525A (en) | Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease | |
AU2002222748A1 (en) | Novel use of diterpene compound as a therapeutic agent of inflammation, immune disease or cancer | |
MXPA03009535A (es) | Comprimido de meloxicam de rapida desintegracion. | |
AU2002338230A1 (en) | Food item for increasing cognitive capacity | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
IL154755A0 (en) | Antitumor theraphy comprising distamycin derivatives | |
USD471434S1 (en) | Drapery hardware bracket | |
USD411894S (en) | Personal illumination unit | |
IL161116A0 (en) | Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension | |
WO2002058707A3 (en) | Method of treatment of type i diabetes with vitamin d compounds | |
PL367630A1 (en) | Use of acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus |